Biology Reference
In-Depth Information
Karim QA, Karim SSA. 1999. South Africa: host to a new and emerging HIV epidemic. Sex
Transm Inf 75: 139±147.
Kelleher AD, Rowland-Jones SL. 2000. Functions of tetramer-stained HIV-speci®c CD4() and
CD8() T cells. Curr Opin Immunol 12: 370±374.
Klenerman P, Zinkernagel RM. 1997. What can we learn about human immunode®cnecy virus
infection from a study of lymphocytic choriomeningitis virus? Immunol Rev 159: 5±16.
Komanduri KV, Viswanathan MN, Wieder ED, Schmidt DK, Bredt BM, Jacobson MA, McCune
JM. 1998. Restoration of cytomegalovirus-speci®c CD4
T-lymphocyte responses after ganci-
clovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 4:
953±956.
Korber B, Moore J, Brander C, Walker B, Haynes B, Koup R. 1999. HIV-1 Sequence Database.
Los Alamos, NM, Los Alamos National Laboratory.
Kroon FP, Rimmelzwaan GF, Roos MT, Osterhaus AD, Hamann D, Miedema F, van Dissel JT.
1998. Restored humoral immune response to in¯uenza vaccination in HIV- infected adults
treated with highly active antiretroviral therapy [In Process Citation]. AIDS 12: F217±F223.
Lalvani A, Dong T, Graham O, Patham AA, Newell H, Hill AV, McMichael A, Rowland-Jones
S. 1997. Optimization of a peptide-based protocol employing IL-7 for in vitro stimulation of
human cytotoxic T lemphocyte precursors. J Immunol Methods 210: 65±77.
Lamhamedi-Cherradi S, Culmann-Penciolelli B, Guy B, Kieny MP, Dreyfus F, Saimot AG, Sereni
D, Sicard D, Levy JP, Gomard E. 1992. Qualitative and quantitative analysis of human cyto-
toxic T-lymphocyte responses to HIV-1 proteins. AIDS 6: 1249±1258.
Larsson M, Jin X, Ramratnam B, Ogg GS, Engelmayer J, Demoitie MA, McMichael AJ, Cox WI,
Steinman RM, Nixon D, Bhardwaj N. 1999. A recombinant vaccinia virus based ELISPOT
assay detects high frequencies of Pol-speci®c CD8 T cells in HIV-1-positive individuals. AIDS
13: 767±777.
Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J,
Greenberg PD, et al. 1999. Characterization of circulating T cells speci®c for tumor-associated
antigens in melanoma patients. Nat Med 5: 677±685.
Letvin NL, Schmitz JE, Jordan HL, Seth A, Hirsch VM, Reimann KA, Kuroda MJ. 1999. Cyto-
toxic T lymphocytes speci®c for the simian immunode®ciency virus. Immunol Rev 170: 127±134.
Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. 1998. Long-lasting recovery in
CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in ad-
vanced HIV-1 disease. Lancet 351: 1682±1686.
Mann D, Garner R, Dayho¨ E, Cao K, Fernandez-Vina M, Davis C, Aronson N, Ruiz N, Birx D,
Michael N. 1998. Major histocompatibility complex genotype is associated with disease pro-
gression and virus load levels in a cohort of human immunode®ciency virus type 1-infected
caucasians and African Americans. J Infect Dis 178: 1799±1802.
McMichael AJ, Phillips RE. 1997. Escape of human immunode®ciency virus from immune control.
Annu Rev Immunol 15: 271±296.
Michie CA, McLean A, Alcock C, Beverley PC. 1992. Lifespan of human lymphocyte subsets de-
®ned by CD45 isoforms. Nature 360: 264±265.
Mocroft A, Bo®ll M, Lipman M, Medina E, Borthwick N, Timms A, Batista L, Winter M, Sabin
C, Johnson M, et al. 1997. CD8
,CD38
lymphocyte percent: a useful immunological marker for
monitoring HIV-1 infected patients. J Acquir Immune De®c Syndr Hum Retrovirol 14: 158±162.
Moss P, Rowland-Jones S, Frodsham P, McAdam S, Giangrande P, McMichael A, Bell J. 1995.
Persistent high frequency of human immunode®ciency virus-speci®c cytotoxic T cells in periph-
eral blood of infected donors. Proc Natl Acad Sci USA 92: 5773±5777.
Murali-Krishna K, Altman JD, Suresh M, Sourdive DJ, Zajac AJ, Miller JD, Slansky J, Ahmed R.
1998. Counting antigen-speci®c CD8 T cells: a reevaluation of bystander activation during viral
infection. Immunity 8: 177±187.
